Nitric oxide depletion is responsible for the adverse effects of vascular endothelial growth factor inhibitors

Nature Clinical Practice Nephrology

Volumn 4, Issue 10, 2008, Pages 536-537

  Thachil, Jecko ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; CLINICAL TRIAL; DISEASE COURSE; DRUG INHIBITION; GLOMERULUS CAPILLARY; HEMOLYSIS; HUMAN; HYPERTENSION; IN VIVO STUDY; KIDNEY BLOOD VESSEL; NEPHROTIC SYNDROME; NONHUMAN; PERIPHERAL ISCHEMIA; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEINURIA; SHORT SURVEY; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASOCONSTRICTION;

ANIMALS; HUMANS; HYPERTENSION; KIDNEY; NITRIC OXIDE; PROTEINURIA; THROMBOSIS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 52949098701     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0907     Document Type: Short Survey

References (15)

1. Eremina V et al. (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358: 1129-1136
2. Papapetropoulos A et al. (1997) Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100: 3131-3139
3. 121- and bFGF-induced increase in collateral blood flow requires normal nitric oxide production. Am J Physiol Heart Circ Physiol 280: H1097-H1104
4. Ziche M et al. (1997) Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 99: 2625-2634
5. Feliers D et al. (2005) VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells. Kidney Int 68: 1648-1659
6. Bussolati B et al. (2001) Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol 159: 993-1008
7. Sugimoto H et al. (2003) Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278: 12605-12608
8. Zhu X et al. (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49: 186-193
9. Datta PK et al. (2006) Effect of nitric oxide synthase inhibition on proteinuria in glomerular immune injury. Exp Biol Med (Maywood) 231: 576-584
10. Waddington S et al. (1996) L-arginine depletion inhibits glomerular nitric oxide synthesis and exacerbates rat nephrotoxic nephritis. Kidney Int 49: 1090-1096
11. Miller KD et al. (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799
12. Cappellini MD (2007) Coagulation in the pathophysiology of hemolytic anemias. Hematology Am Soc Hematol Educ Program 2007: 74-78
13. Dran GI et al. (2002) Protective role of nitric oxide in mice with Shiga toxin-induced hemolytic uremic syndrome. Kidney Int 62: 1338-1348
14. Rother RP et al. (2005). The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 293: 1653-1662
15. Thachil J (2007) Thrombotic thrombocytopenic purpura: is there more than ADAMTS-13? J Thromb Haemost 5: 634-635